Supplementary Figure 6 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion

Noronha et al. (Wed,) studied this question.

www.synapsesocial.com/papers/68e56004e2b3180350efd138 — DOI: https://doi.org/10.1158/1541-7786.27151072

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Supplementary Figure 8 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion· 2024
2. Supplementary Figure 11 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion· 2024
3. Supplementary Figure 3 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion· 2024
4. Supplementary Figure 5 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion· 2024
5. Supplementary Figure 4 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion· 2024